

ATTORNEY DOCKET NO.: 2002834-0046 (CIP10)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Bannon, et al.

Examiner:

Huynh, P.

IF / lay

Serial No.:

09/494,096

Art Unit:

1644

Filing Date:

January 28, 2000

Title:

METHODS AND REAGENTS FOR DECREASING CLINICAL

REACTION TO ALLERGY

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

TRANSMITTAL LETTER

Enclosed are the following documents:

- 1. Form PTO-1449 (10 pages);
- 2. Supplemental Information Disclosure Statement (5 pages);
- 3. Transmittal Letter (1 page);
- 4. Limited Recognition Under 37 CRF § 10.9(b);

Date

5. Return Postcard.

If any additional fees are required to be paid or if any overpayment has been made, please charge same to Deposit Account No. 03-1721.

Respectfully submitted,

Charles E. Lyon, D.Phil

Agent for Applicant

Limited Recognition Under 37 CFR §10.9(b)

Choate, Hall & Stewart Exchange Place 53 State Street Boston, MA 02109 (617) 248-5000

Dated: 10/22/14

Signature

Sandra Saccocia

Typed or Printed Name of person signing certificate

Certificate of Mailing
I certify that this correspondence is being deposited with the United States Postal

Service with sufficient postage as First Class Mail in an envelope addressed to

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

3759714 1.DOC

ATTORNEY DOCKET NO.: 2002834-0046 (CIP10)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Bannon, et al.

Examiner:

Huynh, P.

Serial No.:

09/494,096

Art Unit:

1644

Filing Date:

January 28, 2000

Title:

METHODS AND REAGENTS FOR DECREASING CLINICAL

REACTION TO ALLERGY

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicant requests consideration of this Information Disclosure Statement.

Type of Statement

The present Information Disclosure Statement is:

[] An original Information Disclosure Statement; or

[X] A supplemental Information Disclosure Statement.

Certificate of Mailing

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandrin, VA 22313-1450.

Date

Signature

Sandra Saccocia

Name of Person Signing

Compliance with 37 CFR § 1.97

The present Information Disclosure Statement is being filed:

[]	Pursua	nt to 37	CFR § 1.97(b); no fee or certification is required:
	[]	Within	three months of the filing date of a national application other than
		a conti	nued prosecution application under § 1.53(d);
	[]	Within	three months of the date of entry of the national stage as set forth
		in § 1.4	491 in an international application;
	[]	Before	the mailing of a first Office action on the merits; or
	[]	Before	the mailing of a first Office action after the filing of a request for
		continu	ued examination under § 1.114.
[]	Pursua	nt to 37	CFR § 1.97(c) after the dates listed above but before the mailing
	date of	any of a	a final action under § 1.113, a notice of allowance under § 1.311, or
	an actio	on that o	therwise closes prosecution in the application; Applicant hereby
	either:		
	[]	Certifie	es that either:
		[]	each item of information contained in the information disclosure
			statement was first cited in any communication from a foreign
			patent office in a counterpart foreign application not more than
			three months prior to the filing of the information disclosure
			statement; or
		[]	That no item of information contained in the information
			disclosure statement was cited in a communication from a foreign
			patent office in a counterpart foreign application, and, to the
			knowledge of the person signing the certification after making
			reasonable inquiry, no item of information contained in the
			information disclosure statement was known to any individual

Page 2 of 5 3758946

the information disclosure statement; or Includes herewith the fee set forth in § 1.17(p), [] Pursuant to 37 CFR § 1.97(d), after the mailing date of any final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby both: Certifies that either: each item of information contained in the information disclosure []statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or [] That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement; and

Includes herewith the fee set forth in § 1.17(p).

[]

designated in § 1.56(c) more than three months prior to the filing of

Page 3 of 5 3758946

Content of the Information Disclosure Statement

Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant includes copies of references as indicated below:

- [] A copy of each cited reference not indicated with an asterisk is included;
- [X] Copies of references indicated with an asterisk on the attached form PTO-1449 are not included pursuant to 37 CFR § 1.98(d) because they were previously provided to the United States Patent Office in an Information Disclosure Statement that complies with 37 CFR § 1.98(a)-(c) and was submitted in the following patent application that is relied upon in the present case for an earlier effective filing date under 35 USC § 120:

Serial Number	Filing Date	Status
09/141,220	August 27, 1998	Pending

[] Copies of English translations of one or more non-English references are included.

Applicant hereby makes the following additional information of record in the above-identified application:

Applicant certifies that the Information Disclosure Statement either:

- [X] Does not contain non-English language citations;
- [] Includes one or more translations of a non-English citation; or
- [] Does contain non-English language citations, of which the following is a concise explanation:

Page 4 of 5 3758946

Remarks

The submission of this Information Disclosure Statement should not be construed as a

representation that a search has been made.

The submission of this Information Disclosure Statement shall not be construed to be an

admission that the information cited in the statement is, or is considered to be, material to patentability as

defined in § 1.56(b).

The submission of this Information Disclosure Statement shall not be construed as a

representation that the information cited in the Statement is, or is considered to be, in fact, prior art as

defined by 35 USC §102.

It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other

information, in reaching a determination concerning the patentability of the present claims;

2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited

patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during

the examination of this application; and

3. The citations for the patent(s) and publication(s) be printed on any patent which issues

from this application.

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own

conclusions regarding the relevance of the cited reference(s).

Dated:

16/22/04

Charles E. Lyon, D Phil.

Respectfully submitted,

Agent for Applicant

Limited Recognition Under 37 CFR §10.9(b)

CHOATE, HALL & STEWART Exchange Place 53 State Street Boston, Massachusetts 02109

(617) 248-5000

(617) 248-4000



BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE UNITED STATES PATENT AND TRADEMARK OFFICE

LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Charles Lyon is hereby given limited recognition under 37 CFR § 10.9(b) as an employee of the Choate, Hall & Stewart law firm to prepare and prosecute patent applications wherein the patent applicant is the client of the Choate, Hall & Stewart law firm, and the attorney or agent of record in the applications is a registered practitioner who is a member of the Choate, Hall & Stewart law firm. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Charles Lyon ceases to lawfully reside in the United States, (ii) Charles Lyon's employment with the Choate, Hall & Stewart law firm ceases or is terminated, or (iii) Charles Lyon ceases to remain or reside in the United States on an H1B visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the United States Patent and Trademark Office.

Expires: December 1, 2004

Harry I. Moatz

Director of Enrollment and Discipline

PTO-1449 CAT & TRAD IN RE U.S. Department of ATTY. DOCKET: **APPLICATION NO.:** Commerce 2002834-0046 Patent and Trademark Office 09/494,096 (REV. 8-83) APPLICANT: Bannon, et al. **SUPPLEMENTAL** FILING DATE: GROUP: 1644 INFORMATION DISCLOSURE STATEMENT January 28, 2000 (*Use several sheets if necessary*) U.S. PATENT DOCUMENTS Class Subclass Examiner's U.S. Patent No. **Applicant** Issue Date Initials U.S. PATENT APPLICATIONS Serial Number: **Publication Date:** Examiner's Applicant: Group: Art Unit: Initials: FOREIGN PATENT DOCUMENTS Examiner's Document No. Country Date Translation **Initials** Yes No OTHER DOCUMENTS Examiner's Citation (Including Author, Title, Date, Pertinent Pages, Etc.) **Initials** *Amorim, et al., "Suppression of Airway Eosinophilia by Killed Mycobacterium Vaccae-Induced Allergen-Specific Regulatory T-Cells", Nature Medicine, 8(6): 625-629, 2002. *Asturias, et al., "Is Tropomyosin an Allergen in Anisakis?", Allergy, 55: 898-890, 2000. *Asturias, et al., "Cloning, Isolation, and IgE-Binding Properties of Helixaspersa (Brown Garden Snail) Tropomyosin", Int. Arch Allergy Immunol. 128: 90-96, 2002. *Asturias, et al., "Molecular Characterization of American Cockroach Tropomyosin (Periplaneta Americana Allergen 7), a Cross-Reactive Allergen", The Journal of Immunology, **162**: 4342-4348, 1999. *Bannon, et al., "Engineering, Characterization and in Vitro Efficacy of the Major Peanut Allergens for Use in Immunotherapy", Int. Arch. Allergy Immunol, 124: 70-72, 2001. *Barderas, et al., "Identification and Characterization of Che a 1 Allergen from Chenopodium Album Pollen", Int. Arch. Allergy Immunol. 127: 47-54, 2002.

OCT 2 5 2004

	7					
U.S. Department of Commerce	ATTY. DOCKET: 2002834-0046	IN RE APPLICATION NO.:				
Patent and Trademark Office	09/494,096					
TAL ON DISCLOSURE STATEMENT veral sheets if necessary)	FILING DATE: January 28, 2000	GROUP: 1644				
*Barnes, P.J., "IL-10: A Key Regulator of Allergy, 31 : 667-669, 2001.	Allergic Disease", Clinical	l and Experimental				
 *Bashir, et al., "An Enteric Helminth Infection Protects Against an Allergic Response to Dietary Antigen", <i>The Journal of Immunology</i>, 169: 3284-3292, 2002. *Batanero, et al., "Purification, Amino Acid Sequence and Immunological Characterization of Ole e 6, a Cysteine-Enriched Allergen from Olive Tree Pollen", <i>FEBS Letters</i>, 410: 293-296, 1997. *Beck, et al., "The Polyclonal and Antigen-Specific IgE and IgG Subclass Response of Mice Injected with Ovalbumin in Alum or Complete Freund's Adjuvant", <i>Cellular Immunology</i>, 123: 1-8, 1989. *Bissonnette, et al., "Inhibition of Mast Cell-Mediated Cytotoxicity by IFN-α/β and -γ¹", <i>The Journal of Immunology</i>, 145: 3385-3390, 1990. *Bock, et al., "The Natural History of Food Sensitivity", <i>J.Allergy Clin. Immunol.</i> 69: 173-177, 1982. 						
				*Bock, et al., "Fatalities Due to Anaphylactic Reactions to Foods", <i>J. Allergy Clin. Immunol.</i> 107 : 191-193, 2001.		
				*Brandtzaeg, et al., "Current Understanding of Gastrointestinal Immunoregulation and Its Relation to Food Allergy", <i>Ann. N.Y. Acad. Sci.</i> , 964 : 13-45, 2002.		
				*Burks, et al., "Modification of a Major Peanut Allergen Leads to Loss of IgE Binding", <i>Int. Arch. Allergy Immunol.</i> 118 : 313-314, 1999.		
				*Bush, et al., "Molecular Cloning of a Major Alternaria Alternata Allergen, rAlt a 2", J. Allergy Clin. Immunol. 104: 665-671, 1999.		
*Chang, et al., "Characterization of Enolase Allergen from Rhodotorula Mucilaginosa", <i>J. Biomed. Sci.</i> 9: 645-655, 2002.						
*Dandeu, et al., "Hydrophobic Interaction Chromatography for Isolation and Purification of Equ.c1, the Horse Major Allergen", <i>Journal of Chromatography</i> , 621 : 23-31, 1993.						
_ · · · · · · · · · · · · · · · · · · ·		_				
	*Batanero, et al., "The Polyclonal and Antigen Injected with Ovalbumin in Alum or Comp 123: 1-8, 1989. *Bock, et al., "The Natural History of Food 177, 1982. *Bock, et al., "Fatalities Due to Anaphylac 107: 191-193, 2001. *Brandtzaeg, et al., "Current Understanding Relation to Food Allergy", Ann. N.Y. Acad. *Burks, et al., "Modification of a Major Pe Arch. Allergy Immunol. 118: 313-314, 1999. *Bush, et al., "Molecular Cloning of a Major Pe Arch. Allergy Immunol. 110: 104: 665-671, 1999. *Chang, et al., "Characterization of Enolase Biomed. Sci. 9: 645-655, 2002. *De Jong, et al., "Identification and Partial	Patent and Trademark Office Patent and Trademark Office Patent and Trademark Office APPLICANT: Bannon, of FILING DATE: January 28, 2000 *Barnes, P.J., "IL-10: A Key Regulator of Allergic Disease", Clinical Allergy, 31: 667-669, 2001. *Bashir, et al., "An Enteric Helminth Infection Protects Against an A Dietary Antigen", The Journal of Immunology, 169: 3284-3292, 2002 *Batanero, et al., "Purification, Amino Acid Sequence and Immunolog Ole e 6, a Cysteine-Enriched Allergen from Olive Tree Pollen", FEBS 1997. *Beck, et al., "The Polyclonal and Antigen-Specific IgE and IgG Sub Injected with Ovalbumin in Alum or Complete Freund's Adjuvant", C 123: 1-8, 1989. *Bissonnette, et al., "Inhibition of Mast Cell-Mediated Cytotoxicity b Journal of Immunology, 145: 3385-3390, 1990. *Bock, et al., "The Natural History of Food Sensitivity", J.Allergy Cl. 177, 1982. *Bock, et al., "Fatalities Due to Anaphylactic Reactions to Foods", J. 107: 191-193, 2001. *Brandtzaeg, et al., "Current Understanding of Gastrointestinal Immun Relation to Food Allergy", Ann. N.Y. Acad. Sci., 964: 13-45, 2002. *Burks, et al., "Modification of a Major Peanut Allergen Leads to Los Arch. Allergy Immunol. 118: 313-314, 1999. *Bush, et al., "Molecular Cloning of a Major Alternaria Alternata Allergy Clin. Immunol. 104: 665-671, 1999. *Chang, et al., "Characterization of Enolase Allergen from Rhodotoru Biomed. Sci. 9: 645-655, 2002. *Dandeu, et al., "Hydrophobic Interaction Chromatography for Isolation.				

\2.					
PTO-1449 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2002834-0046	IN RE APPLICATION NO.: 09/494,096		
		APPLICANT: Bannon, et al.			
	TAL ON DISCLOSURE STATEMENT eral sheets if necessary)	FILING DATE: January 28, 2000	GROUP: 1644		
	*Diaz-Perales, et al., "Lipid-Transfer Prote Reactivity Among Proteins of Artemisia Po Different IgE-Binding Capacities", Clinical	ollen, Castanea Nut and Ro	saceae Fruits, with		
	*Diaz-Perales, et al., "Characterization of Asparagus Allergens: A Relevant Role of Lipid Transfer Proteins", J. Allergy Clin. Immunol. 110: 790-796, 2002.				
	*Dorion, et al., "The Production of Interferon-γ in Response to a Major Peanut Allergy, Ara h II, Correlates with Serum Levels of IgE Anti-Ara h II", J. Allergy Clin. Immunol. 93: 93-99, 1994. *Durham, et al., "Immunologic Changes Associated with Allergen Immunotherapy", The Journal of Allergy and Clinical Immunology, 102(2): 157-164, 1998. *Erb, et al., "Atopic Disorders: A Default Pathway in the Absence of Infection?", Immunol. Today, 20: 317-322, 1999. *Eriksson, et al., "Cloning and Characterisation of a Group II Allergen from the Dust Mite Tyrophagus Putrescentiae", Eur. J. Biochem. 251: 443-447, 1998. *Eriksson, et al., "Cloning of Three New Allergens from the Dust Mite Lepidoglyphus Destructor Using Phage Surface Display Technology", Eur. J. Biochem. 268: 287-294, 2001.				
	*Fahlbusch, et al., "Purification and Partial Characterization of the Major Allergen, Cav p 1, from Guinea Pig Cavia Porcellus", <i>Allergy</i> , 57 : 417-422, 2002.				
	*Fiorentino, et al., "Two Types of Mouse T Helper Cell", J. Exp. Med. 170: 2081-2095, 1989.				
	*Francis, et al., "Induction of IL-10 ⁺ CD4 ⁺ CD25 ⁺ T Cells by Grass Pollen Immunotherapy", <i>J. Allergy Clin. Immunol.</i> 111: 1255-1261, 2003. *Gafvelin, et al., "Cross-Reactivity Studies of a New Group 2 Allergen from the Dust Mite Glycyphagus Domesticus, Gly d 2, and Group 2 Allergens from Dermatophagoides Pteronyssinus, Lepidoglyphus Destructor, and Tyrophagus Putrescentiae with Recombinant Allergens", <i>J. Allergy Clin. Immunol.</i> 107: 511-518, 2001.				
	*Giuliani, et al., "Isolation and Purification Pollen", <i>Allergy</i> , 42 : 434-440, 1987.	of a Major Allergen from	Parietaria Officinalis		

OCT 2 5 2004

IN RE U.S. Department of ATTY. DOCKET: APPLICATION NO.: Commerce 2002834-0046 09/494,096 Patent and Trademark Office (REV. 8-83) APPLICANT: Bannon, et al. **SUPPLEMENTAL** FILING DATE: **GROUP: 1644** INFORMATION DISCLOSURE STATEMENT January 28, 2000 (*Use several sheets if necessary*) *Hansen, et al., "Vaccination with Heat-Killed Listeria as Adjuvant Reverses Established Allergen-Induced Airway Hyperreactivity and Inflammation: Role of CD8⁺ T Cells and IL-18", The Journal of Immunology, 164: 223-230, 2000. *Helm, et al., "Isolation and Characterization of a Clone Encoding a Major Allergen (Bla g Bd90K) Involved in IgE-Mediated Cockroach Hypersensitivity", J. Allergy Clin. Immunol. 98: 172-180, 1996. *Hilger, et al., "Sequence of the Gene Encoding cat (Felis Domesticus) Serum Albumin", Gene, 169: 295-296, 1996. *Himly, et al., "Art v 1, the Major Allergen of Mugwort Pollen, is a Modular Glycoprotein with a Defensin-Like and a Hydroxyproline-Rich Domain", FASEB J., 17: 106-108, 2003. *Hoffman, et al., "Occupational Allergy to Bumblebees: Allergens of Bombus Terrestris", J. Allergy Clin. Immunol. 108: 855-860, 2001. *Hoffman, et al., "Allergens in Hymenoptera Venom XXVII: Bumblebee Venom Allergy and Allergens", J. Allergy Clin. Immunol. 97: 812-821, 1996. *Hoffman, et al., "Allergens in Bee Venom, III. Identification of Allergen B of Bee Venom as an Acid Phosphatase", J. Allergy Clin. Immunol. 59(5): 364-366, 1977. *Horiuti, et al., "Variable Expression of Pathogenesis-Related Protein Allergen in Mountain Cedar (Juniperus Ashei) Pollen", The Journal of Immunology, 164: 2188-2192, 2000. *Horner, et al., "Identification of the Allergen Psi c 2 from the Basidiomycete Psilocybe Cubensis as a Fungal Cyclophilin". Int. Arch Allergy Immunol. 107: 298-300, 1995. *Howard, et al., "Regulation of B-Cell Growth and Differentiation by Soluble Factors", Ann. Rev. Immunol. 1: 307-333, 1983. *Hsu, et al., "Differential Effects of IL-4 and IL-10 on IL-2-Induced IFN-y Synthesis and Lymphokine-Activated Killer Activity", International Immunology, 4(5): 563-569, 1992. *Ichikawa, et al., "Molecular Cloning, Expression and Modelling of Cat Allergen, Cystatin (Fel d 3), A Cysteine Protease Inhibitor", Clinical and Experimental Allergy, 31: 1279-1286, 2001. *Jankulovic, et al.. "Isolation and Biochemical Characterization of a Thaumatin-Like Kiwi Allergen", J. Allergy Clin. Immunol. 110: 805-810, 2002.

@ @	7 2 5 2004 35	····			
PTO-1449 (REV. 8-83)	& TRADEMARY	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2002834-0046	IN RE APPLICATION NO.: 09/494,096	
,	Tutom and Transmant Street		APPLICANT: Bannon, et al.		
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		FILING DATE: January 28, 2000	GROUP: 1644		
		aki, et al., "Transforming Growth sease at an Early Age", J. Allergy	•		
	*Kleine-Tebbe, et al., "Severe Oral Allergy Syndrome and Anaphylactic Reactions Caused by a Bet v 1-Related PR-10 Protein in Soybean, SAM22", <i>J. Allergy Clin. Immunol.</i> 110 : 797-804, 2002.				
	*Kowalski, et al., "Mechanisms of Specific Immunotherapy of Allergic Diseases", <i>Allergy</i> , 53 : 485-492, 1998.				
	*Ledesman, et al., "Cloning, Expression and Characterization of a Novel Four EF-Hand Ca ²⁺ - Binding Protein from Olive Pollen with Allergenic Activity", <i>FEBS Letter</i> , 466 : 192-196, 2000.				
	*Lee, et al., "Oral Administration of Il-12 Suppresses Anaphylactic Reactions in a Murine Model of Peanut Hypersensitivity", Clinical Immunology, 101(2): 220-228, 2001.				
	*Leung, et al., "Effect of Anti-IgE Therapy in Patients with Peanut Allergy", N. Engl. J. Med. 348: 986-993, 2003.				
	*Li, et al., "A Murine Model of Peanut Anaphylaxis: T- and B-Cell Responses to a Major Peanut Allergen Mimic Human Responses", J. Allergy Clin. Immunol. 106: 150-158, 2000.				
	*Li, et al., "Novel Approaches for the Treatment of Food Allergy", Current Opinion in Allergy and Clinical Immunology, 2: 273-278, 2002.				
	*Li, et al., "Engineered Recombinant Peanut Protein and Heat-Killed Listeria Monocytogenes Coadministration Protects Against Peanut-Induced Anaphylaxis in a Murine Model", <i>The Journal of Immunology</i> , 170 : 3289-3295, 2003.				
	*Li, et al., "Strain-Dependent Induction of Allergic Sensitization Caused by Peanut Allergen DNA Immunization in Mice", <i>The Journal of Immunology</i> , 162 : 3045-3052, 1999.				
	*Lombardero, et al., "cDNA Sequence Analysis of the Main Olive Allergen, Ole e I", Clinical and Experimental Allergy, 24: 765-770, 1994.				
	-	t al., "Characteristics of Hyperse Binding Protein (Hal-m-1) in Ab 548, 1997.	-		



PTO-1449 U.S. Department of IN RE ATTY. DOCKET: APPLICATION NO.: Commerce 2002834-0046 Patent and Trademark Office (REV. 8-83) 09/494,096 APPLICANT: Bannon, et al. **SUPPLEMENTAL** FILING DATE: GROUP: 1644 INFORMATION DISCLOSURE STATEMENT January 28, 2000 (*Use several sheets if necessary*) *Lorentz, et al., "Human Intestinal Mast Cells Produce IL-5 in Vitro Upon IgE Receptor Cross-Linking and In Vivo in the Course of Intestinal Inflammatory Disease" Eur. J. Immunol. **29**: 1496-1503, 1999. *Melen, et al., "Molecular Cloning of Per a 1 and Definition of the Cross-Reactive Group 1 Cockroach Allergens", J. Allergy Clin. Immunol. 103: 859-864, 1999. *Moneo, et al., "Isolation and Characterization of Tha p 1, A Major Allergen from the Pine Processionary Caterpillar Thaumetopoea Pityocampa", Allergy, 58: 34-37, 2003. *Moneo, et al., "Isolation and Characterization of a Major Allergen from the Fish Parasite Anisakis Simplex", J. Allergy Clin. Immunol. 106: 177-182, 2000. *Monsalve, et al.. "Detection, Isolation and Complete Amino Acid Sequence of an Aeroallergenic Protein from Rapeseed Flour", Clinical and Experimental Allergy, 27: 833-841, 1997. *Morafo, et al., "Genetic Susceptibility to Food Allergy is Linked to Differential T_H²-T_H¹ Responses in C3H/HeJ and BALB/c Mice", J. Allergy Clin. Immunol. 111: 1122-1128, 2003. *Mosmann, et al., "Thi and Th2 Cells: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties", Ann. Rev. Immunol. 7: 145-173, 1989. *Mutius, et al., "The Environmental Predictors of Allergic Disease", J. Allergy Clin. Immunol. **105**: 9-19, 2000. *Onishi, et al., "Two-Dimensional Electrophoresis of Malassezia Allergens for Atopic Dermatitis and Isolation of Mal f 4 Homologs with Mitochondrial Malate Dehydrogenase", Eur. J. Biochem. 261: 148-154, 1999. *Onizuka, et al., "Purification of the Major Allergen of Red Soft Coral (Dendronephthya Nipponica)", Int. Arch. Allergy Immunol, 125: 135-143, 2001. *Oppenheimer, et al., "Treatment of Peanut Allergy with Rush Immunotherapy", J. Allergy Clin. Immunol. 90: 256-262, 1992. *Paddock, et al., "Identification, Cloning, and Recombinant Expression of Procalin, a Major Triatomine Allergen", The Journal of Immunology, 167: 2694-2699, 2001. *Palosuo, et al., "Wheat ω-5 Gliadin is a Major Allergen in Children with Immediate Allergy

to Ingested Wheat", J. Allergy Clin. Immunol. 108: 634-638, 2001.

001 2 5 2004	<u> </u>			
PTO-1449 TRADENIA (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2002834-0046	IN RE APPLICATION NO. 09/494,096	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT: Bannon, et al.		
		FILING DATE: January 28, 2000	GROUP: 1644	
	ello, et al., "The Major Allergen of n", Journal of Chromatography B,	•	Indicum) is a 2S	
Patients	ello, et al., "Allergenic Cross-React with Oral Allergy Syndrome: An I ol. 94: 699-707, 1994.			
Periphe	*Pierkes, et al., "Decreased Release of Histamine and Sulfidoleukotrienes by Hum Peripheral Blood Leukocytes After Wasp Venom Immunotherapy is Partially Due of IL-10 and IFN-γ Production of T Cells", J. Allergy Clin. Immunol. 103: 326-33			
	and American Cockroach", The Jo	with Tandem Amino Acid Repeats Derived from ournal of Biological Chemistry, 273(46): 30801- ession of Blo t 11, the Blomia Tropicalis Allergen Elergy Immunol. 126: 286-293, 2001.		
l l				
Three Ig	*Rasool, et al., "Cloning, Characterization and Expression of Complete Coding Sequences of Three IgE Binding Malassezia Furfur Allergens, Mal f 7, Mal f 8 and Mal f 9", Eur. J. Biochem. 267: 4355-4361, 2000.			
	*Romagnani, et al., "The Role of Lymphocytes in Allergic Disease", J. Allergy Clin. Immunot 105: 399-408, 2000.			
*Rook,	*Rook, et al., "Give us this Day our Daily Germs", Immunology Today, 19: 113-116, 1998.			
Respons	*Saarinen, et al., "Transforming Growth Factor-β1 in Mothers' Colostrum and Immuno Responses to Cows' Milk Proteins in Infants with Cows' Milk Allergy", J. Allergy Clin Immunol. 104: 1093-1098, 1999.			
Tropom	, et al., "Cloning and Characterisati yosin and α -Tubulin, from the Mite l. 130: 258-265, 2003.			
	on, et al., "Fatal and Near-Fatal Andents", N. Engl. J. Med. 327: 380-38		ood in Children and	
	on, Hugh., "Food Allergy. Part 1: In of Allergy and Clinical Immunolog			

	, to			
PTO-1449 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2002834-0046	IN RE APPLICATION NO.: 09/494,096	
		APPLICANT: Bannon, et al.		
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		FILING DATE: January 28, 2000	GROUP: 1644	
	*Sanchez-Monge, et al., "Isolation and Cha Lentils", J. Allergy Clin. Immunol. 106: 95		Allergens from Boiled	
	*Santos, et al., "Cockroach Allergens and Asthma in Brazil: Identification of Tropomyosin as a Major Allergen with Potential Cross-Reactivity with Mite and Shrimp Allergens", <i>J. Allergy Clin. Immunol.</i> 104 : 329-337, 1999.			
	*Saxena, et al., "cDNA Cloning, Expression and Characterization of an Allergenic L3 Ribosomal Protein of Aspergillus Fumigatus" Clin. Exp. Immunol, 134: 86-91, 2003.			
	*Schade, et al., "Differences In Antigen-Specific T-Cell Responses Between Infants with Atopic Dermatitis with and without Cow's Milk Allergy: Relevance of T _H 2 Cytokines", <i>J. Allergy Clin. Immunol.</i> 106 : 1155-1162, 2000.			
	*Shen, et al., "Characterization of Allergens from Penicillium Oxalicum and P. Notatum by Immunoblotting and N-Terminal Amino Acid Sequence Analysis", <i>Clinical and Experimental Allergy</i> , 29 : 642-651, 1999. *Shen, et al., "Molecular Cloning and Immunological Characterization of the House Dues Mite Allergen Der f 7", <i>Clinical and Experimental Allergy</i> , 25 : 1000-1006, 1995.			
	*Sicherer, et al., "Prevalence of Peanut and Tree Nut Allergy in the US Determined by a Random Digit Dial Telephone Survey", <i>J. Allergy Clin. Immunol.</i> 103 : 559-562, 1999.			
	*Smith, et al., "Sequence Polymorphisms and Antibody Binding to the Group 2 Dust Mite Allergens", <i>Int. Arch. Allergy Immunol.</i> 124 : 61-63, 2001.			
	*Smith, et al., "The Molecular Basis of Antigenic Cross-Reactivity Between the Group 2 Mite Allergens", J. Allergy Clin Immunol. 107: 977-984, 2001.			
	*Snapper, et al., "Interferon-y and B Cell Stimulatory Factor-1 Reciprocally Regulate Ig Isotype Production", Science, 236: 944-947, 1987.			
	*Sommergruber, et al., "Molecular Charact Protein from Carrot and its Cross-Reactivit Experimental Allergy, 29: 840-847, 1999.			
	*Stanley, et al., "Identification and Mutatio Epitopes of the Major Peanut Allergen Ara 342(2): 244-253, 1997.	•		

OCT 2 5 2004 PTO-1449 U.S. Department of ATTY. DOCKET: **IN RE APPLICATION NO.:** Commerce 2002834-0046 09/494,096 Patent and Trademark Office (REV. 8-83) APPLICANT: Bannon, et al. **SUPPLEMENTAL** GROUP: 1644 FILING DATE: INFORMATION DISCLOSURE STATEMENT January 28, 2000 (*Use several sheets if necessary*) *Strobel, et al., "Immune Responses to Dietary Antigens: Oral Tolerance", Immunology Today, 19: 173-181, 1998. *Strobel, et al., "Oral Tolerance, Systemic Immunoregulation, and Autoimmunity" Ann. N.Y. Acad. Sci. 958: 47-58, 2002. *Tejera, et al., "Identification, Isolation, and Characterization of Ole e 7, a New Allergen of Olive Tree Pollen", J. Allergy Clin Immunol, 104: 797-802, 1999. *Tinghino, et al., "Molecular Characterization of a Cross-Reactive Juniperus Oxycedrus Pollen Allergen, Jun o 2: A Novel Calcium-Binding Allergen", J. Allergy Clin Immunol, 101: 772-777, 1998. *Tsai, et al., "Sequence Analysis and Expression of a cDNA Clone Encoding a 98-kDa Allergen in Dermatophagoides Farinae", Clinical and Experimental Allergy, 29: 1606-1613,

1999.

*Turcanu, et al., "Characterization of Lymphocyte Responses to Peanuts in Normal Children, Peanut-Allergic Children, and Allergic Children who Acquired Tolerance to Peanuts", *The*

*Weiner, et al., "Oral Tolerance: Immune Mechanisms and Treatment of Autoimmune

Journal of Clinical Investigation, 111(7): 1065-1072, 2003.

Diseases", Immunology Today, 18: 335-343, 1997.

PTO-1449 Type U.S. Department of

PTO-1449 IN RE U.S. Department of ATTY. DOCKET: APPLICATION NO.: Commerce 2002834-0046 Patent and Trademark Office 09/494,096 (REV. 8-83) APPLICANT: Bannon, et al. **SUPPLEMENTAL** GROUP: 1644 FILING DATE: INFORMATION DISCLOSURE STATEMENT January 28, 2000 (*Use several sheets if necessary*) 244, 1998. *Yeung, et al., "Heat-Killed Listeria Monocytogenes as an Adjuvant Converts Established Murine Th2-Dominated Immune Responses into Th1-Dominated Responses", The Journal of Immunology, 161: 4146-4152, 1998. *Yi, et al., "Identification of Shared and Unique Immunoglobulin E Epitopes of the Highly Conserved Tropomyosins in Blomia Tropicalis and Dermatophagoides Pteronyssinus", Clin. Exp. Allergy, 32: 1203-1210, 2002. *Yocum, et al., "Epidemiology of Anaphylaxis in Olmsted County: A Population-Based Study", J. Allergy Clin. Immunol. 104: 452-456, 1999. *Yokoyama, et al., "Purification, Identification, and cDNA Cloning of Jun a 2, the Second Major Allergen of Mountain Cedar Pollen", Biochemical and Biophysical Research Communications, 275: 195-202, 2000.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

The Journal of Immunology, 170: 445-453, 2003.

*Yu, et al., "Proteomics and Immunological Analysis of a Novel Shrimp Allergen, Pen M 2",

3758874